Table 3.
Proportion of Patients Achieving OCS Dose Reduction and/or Interruption During Benralizumab Treatment in Naïve, Bio-Experienced, Omalizumab, and Mepolizumab Groups After 48 and 96 Weeks
| OCS Reduction from Index Date | Naive at 48 Weeks N (%) (N=25) | Naive at 96 Weeks N (%) (N=22) | Bio-Experienced at 48 Weeks N (%) (N=9) | Bio-Experienced at 96 Weeks N (%) (N=8) | Omalizumab at 48 Weeks N (%) (N=3) | Omalizumab at 96 Weeks N (%) (N=3) | Mepolizumab at 48 Weeks N (%) (N=6) | Mepolizumab at 96 Weeks N (%) (N=5) |
|---|---|---|---|---|---|---|---|---|
| Interruption | 13 (52.0) | 14 (63.6) | 5 (55.6) | 4 (50.0) | 1 (33.3) | 1 (33.3) | 4 (66.7) | 3 (60.0) |
| Any reduction (including interruption) | 15 (60.0) | 15 (68.2) | 6 (66.7) | 5 (62.5) | 2 (66.7) | 2 (66.7) | 4 (66.7) | 3 (60.0) |
| ≥90% dose reduction | 13 (52.0) | 14 (63.6) | 5 (55.6) | 4 (50.0) | 1 (33.3) | 1 (33.3) | 4 (66.7) | 3 (60.0) |
| ≥75% dose reduction | 13 (52.0) | 14 (63.6) | 5 (55.6) | 4 (50.0) | 1 (33.3) | 1 (33.3) | 4 (66.7) | 3 (60.0) |
| ≥25% dose reduction | 15 (60.0) | 15 (68.2) | 5 (55.6) | 4 (50.0) | 1 (33.3) | 1 (33.3) | 4 (66.7) | 3 (60.0) |
| No reduction | 10 (40.0) | 7 (31.8) | 3 (33.3) | 3 (37.5) | 1 (33.3) | 1 (33.3) | 2 (33.3) | 2 (40.0) |
Notes: OCS dosage is expressed as daily mg (prednisone equivalent). Data are expressed as N (%).
Abbreviations: N, number of patients; OCS, oral corticosteroids.